Bergen, 23 May 2024: BerGenBio ASA held its annual general meeting today
digitally through Lumi AGM. All resolutions were made in accordance with the
proposals from the board of directors and the nomination committee, including,
but not limited to, approval of the 2023 annual accounts, election of a member
to the board of directors, the reverse share split, the share capital reduction
and the authorisations to the board of directors.

The reverse share split is expected to be completed as soon as possible during
the next weeks. Shareholders who want to avoid rounding's of fraction shares may
position themselves with a shareholding divisible by 100 by purchase or sell
shares before completion of the reverse share split.

The minutes from the annual general meeting are attached hereto and will also be
made available on the company's website www.bergenbio.no.

For further information, please contact:

Martin Olin, CEO, BerGenBio ASA, ir@bergenbio.com

Rune Skeie, CFO, BerGenBio ASA, rune.skeie@bergenbio.com

About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing
transformative drugs targeting AXL as a potential cornerstone of therapy for
aggressive diseases, including cancer and severe respiratory infections. The
Company is focused on its proprietary lead candidate bemcentinib a potentially
first-in-class selective AXL inhibitor in development for STK11 mutated NSCLC
and severe respiratory infections.

BerGenBiois based in Bergen, Norway with a subsidiary in Oxford, UK. The company
is listed on the Oslo Stock Exchange (ticker: BGBIO). For more information,
visit www.bergenbio.com

This information is subject to the disclosure requirements pursuant to Section 5
-12 of the Norwegian Securities Trading Act.